Skip to main content
. Author manuscript; available in PMC: 2016 Jul 22.
Published in final edited form as: Clin Cancer Res. 2015 Mar 9;21(11):2558–2568. doi: 10.1158/1078-0432.CCR-14-2506

Figure 3.

Figure 3

Evaluation of SAR405838 in RS4;11 xenografts or sublines treated with Bcl-2 inhibitors. A, RS4;11 parental and sublines previously exposed to ABT-737 in vivo (G3M1-G3M8) and in vitro (ABTR1 and ABTR2) were treated for 4 days with SAR405838 and cell viability was determined by a WST assay. B, RS4;11 parental and representative sublines were treated with SAR405838 for 24 h for apoptosis analysis by flow cytometry with Annexin V/P.I. double staining. C, RS4;11 parental and two representative sublines (G3M1 and G3M6) were treated with SAR405838 for 24 h for immunoblotting of p53 and p53-regulated proteins and biochemical markers of apoptosis.